Keros Therapeutics, Inc.
KROS Healthcare Biotechnology
In the quarter to June 2026, revenue fell 99.8%, EPS fell 90.8% and free cash flow grew 32.2%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow KROS
Keros Therapeutics, Inc. (KROS) Piotroski F-score
Keros Therapeutics, Inc.'s Piotroski F-score for fiscal 2025 is 7 out of 9: 7 of nine tests of profitability, leverage and efficiency passed.
Piotroski F-score, annual
Embed this chart
Annual newest first
| Period | Piotroski F-score | Change (points) |
|---|---|---|
| FY2025 | 7 | — |
How fiscal 2025’s score is made up
| Test | This year | Year before | Result | Points |
|---|---|---|---|---|
| Positive return on assets | 18.24% | (38.01%) | Pass | 1 |
| Positive operating cash flow | 107.51m | (160.87m) | Pass | 1 |
| Rising return on assets | 18.24% | (38.01%) | Pass | 1 |
| Cash flow above net income | 20.49m | 26.48m | Pass | 1 |
| Falling long-term leverage | 0.00 | 0.00 | Pass | 1 |
| Rising current ratio | 15.45 | 21.45 | Fail | 0 |
| No new shares issued | 37,221,000 | 37,438,000 | Pass | 1 |
| Rising gross margin | 100.00% | 100.00% | Fail | 0 |
| Rising asset turnover | 0.51 | 0.01 | Pass | 1 |
| Piotroski F-score | Strong — most fundamentals improved | 7 | ||
How the Piotroski F-score works
One point for each of nine tests, this fiscal year against the one before: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, a rising current ratio, no new shares issued, a rising gross margin and rising asset turnover. The ratios are the ones on this site, so each can be checked.
Joseph Piotroski (2000) called 8–9 high and 0–1 low; reading it in three bands is the common convention:
| 7–9 | Strong — most fundamentals improved |
|---|---|
| 4–6 | Mixed |
| 0–3 | Weak — most fundamentals deteriorated |
Where this differs from the paper: return on assets is on average rather than beginning-of-year assets, and weighted basic shares stand in for shares issued. The score is shown only when all nine tests can be worked out, which takes three fiscal years; banks and insurers, which report no current assets or gross profit, have none.
Piotroski F-score against peers
| Company | Piotroski F-score |
|---|---|
| KROS Keros Therapeutics, Inc. | 7 |
| SLGL Sol-Gel Technologies Ltd. compare | 6 |
| CAMP CAMP4 Therapeutics Corporation compare | 4 |
| LXEO Lexeo Therapeutics, Inc. compare | 4 |
| PLX Protalix BioTherapeutics, Inc. compare | 3 |
| MGNX MacroGenics, Inc. compare | 3 |
| GLSI Greenwich LifeSciences, Inc. compare | — |
| PYXS Pyxis Oncology, Inc. compare | — |
| EVMN Evommune Inc. compare | — |
What Piotroski F-score is
The Piotroski F-Score tells an investor how many signs of improving profitability, funding and efficiency a company shows against a year earlier.
One point for each of nine tests against a year earlier: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, rising current ratio, no new shares issued, rising gross margin, and rising asset turnover